(lp0
S"Why Rigel Pharmaceuticals, Inc. Got Hammered Today Motley Fool - Oct 20, 2016 Rigel Pharmaceuticals  is down 23% at 11:30 a.m. EDT after the company reported a second phase 3 clinical trial testing for its spleen tyrosine kinase inhibitor, fostamatinib, in patients with adult chronic/persistent immune ...Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term ... - PR Newswire Stock Update : Here's Why Rigel Pharmaceuticals, Inc. Shares Are ... - Smarter Analyst"
p1
aS"Rigel Pharmaceuticals Inc: Hits 4-month high Times of India - Mar 8, 2017 ... ** Drug developer's shares rise as much as 14.2 pct to $2.98 - their highest intraday level since mid-November. ** Rigel on Tuesday indicates it is on track to submit a U.S. marketing application in Q1 for its experimental drug fostamatinib to ..."
p2
aS"Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and ... PR Newswire  - Mar 7, 2017 &quot;We believe that the favorable safety profile and demonstrated efficacy of fostamatinib may make it an excellent treatment option for patients with chronic ITP,&quot; said Raul Rodriguez, Rigel's president and chief executive officer. &quot;The company expects ...Rigel Pharmaceuticals Inc.  Plunges 6.99% on March 06 - Equities.comRigel Pharmaceuticals, Inc.  Issues Quarterly Earnings Results - Chaffey Breeze"
p3
aS"Here's Why Rigel Pharmaceuticals, Inc. is Skyrocketing Today Motley Fool - Aug 30, 2016 What: Shareholders of Rigel Pharmaceuticals , a small-cap clinical stage biopharma, are having a pleasant Tuesday.BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated - BenzingaWhy Rigel Pharma Is Making a Run - 24/7 Wall St."
p4
aS'Why You Should Own Rigel Pharmaceuticals, Inc. Seeking Alpha - Jul 18, 2016 Rigel Pharmaceuticals Inc.  is a clinical stage biotech company with a market cap of approximately $200 million.'
p5
aS"Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing ... PR Newswire  - Jan 16, 2017 SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals  today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of&nbsp;..."
p6
aS'Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year ... PR Newswire  - Feb 28, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.  today announced that it will report its fourth quarter and year end 2016 financial results after market close on Tuesday, March 7, 2017.Rigel Pharmaceuticals Inc.  Moves Lower on Volume Spike for February 28 - Equities.com'
p7
aS"Rigel Restructures to Focus on Fostamatinib Commercialization PR Newswire  - Sep 15, 2016 About Rigel  Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology.Why this Peninsula biotech's layoffs aren't necessarily a bad thing "
p8
aS"Fostamatinib Study Results Continue to Trend Positive PR Newswire  - Jan 30, 2017 30, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.  today announced updates from the clinical program of fostamatinib in patients with chronic immune thrombocytopenic purpura .Rigel Pharmaceuticals  Stock: NDA Coming Soon! - CNA Finance Rigel's fostamatinib still positive in late-stage extension study; shares ... - Seeking Alpha"
p9
aS'Rigel Pharmaceuticals Inc.  Soars 7.46% on March 13 Equities.com - Mar 13, 2017 Rigel Pharmaceuticals Inc.  had a good day on the market for Monday March 13 as shares jumped 7.46% to close at $2.88.'
p10
a.